Scott D Hampton

US Patent:

20060110429, May 25, 2006

Filed:

Nov 16, 2005

Appl. No.:

11/280377

Inventors:

Andreas Reiff - San Marino CA, US
Scott Hampton - Cumming GA, US
Richard Payne - Roswell GA, US

International Classification:

A61K 39/395
A61F 2/00

US Classification:

424427000, 424145100

Abstract:

An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion, and a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent. When the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time.

US Patent:

20090214619, Aug 27, 2009

Filed:

Mar 18, 2009

Appl. No.:

12/406876

Inventors:

Andreas REIFF - San Marino CA, US
Scott HAMPTON - Cumming GA, US
Richard PAYNE - Winston-Salem NC, US

Assignee:

THERAKINE LTD. - Cumming GA

International Classification:

A61F 2/14
A61K 39/395
A61K 38/20

US Classification:

424427, 4241331, 424 852

Abstract:

An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion, and a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent. When the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time.

US Patent:

20100028328, Feb 4, 2010

Filed:

Jun 12, 2006

Appl. No.:

12/304381

Inventors:

Andreas Reiff - San Marino CA, US
Scott Hampton - Cumming GA, US

Assignee:

THERAKINE, LTD. - Cumming GA

International Classification:

A61K 39/395
A61K 48/00
A61K 38/00
A61P 27/02

US Classification:

4241301, 514 44 R, 514 2

Abstract:

A topical eye solution for the treatment of corneal, scleral, or conjunctival diseases. In one embodiment of the present invention, the eye solution comprises a saline-based fluid, and an effective amount of at least one therapeutic compound or agent, wherein when at least one drop of the eye solution is applied to the surface of an eye, the therapeutic compound or agent is released to the cornea and conjunctiva of the eye.

US Patent:

20170065579, Mar 9, 2017

Filed:

Sep 7, 2016

Appl. No.:

15/258288

Inventors:

Andreas Voigt - Berlin, DE
Annette Assogba-Zandt - Berlin, DE
Andreas Reiff - San Marino CA, US
Scott Hampton - Tarpon Springs FL, US

International Classification:

A61K 31/485
A61K 47/36
A61K 9/00
A61K 9/16
A61K 9/10

Abstract:

The present invention belongs to the field of sustained drug release, and provides drug delivery compositions and methods of manufacturing drug delivery compositions.